| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 3MM | -38% |
| Operating Income | -32.6MM | +13% |
| Operating Expenses | 35.6MM | +5% |
| Net Income | -32.3MM | +15% |
| R&D | 28.4MM | +12% |
| G&A | 6.6MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations"
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology,
Are you feeling good about the stock market? You should. The market continued to show strength in early 2024, which is all the more reason to rid your portfolio of F-rated stocks. When the stock market’s this strong, it’s no time to consolidate your positions around bottom-dwellers at bargain prices. This is a time to capitalize on the market’s momentum and look for stocks that are already strong. So far in 2024, the Dow Jones Industrial Average is up more than 2%, topping 38,000. The Nasdaq Com
As you might know, Cara Therapeutics, Inc. ( NASDAQ:CARA ) last week released its latest full-year, and things did not...
Cara Therapeutics ( NASDAQ:CARA ) Full Year 2023 Results Key Financial Results Revenue: US$21.0m (down 50% from FY...
Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript March 4, 2024 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.57. CARA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]
Q4 2023 Cara Therapeutics Inc Earnings Call
Cara (CARA) delivered earnings and revenue surprises of -3.51% and 28.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nas
Just because a business does not make any money, does not mean that the stock will go down. For example, although...